US-based giant Merck & Co., Inc. (NYSE: MRK) announced receiving approval from the Hainan Medical Products Administration for its Winrevair (sotatercept-csrk) to be imported by Shanghai Ruijin Hospital’s Hainan subsidiary. This approval is significant as it provides a new treatment option for patients with pulmonary arterial hypertension (PAH) in China.
Understanding Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a rare, progressive, and life-threatening vascular disease caused by multiple factors. It is characterized by excessive proliferation of pulmonary artery wall cells, leading to pulmonary artery stenosis and abnormal contraction. This ultimately results in the constriction of pulmonary arterioles and elevated blood pressure in the pulmonary circulation. Without timely and effective treatment, PAH can progress to right heart failure, endangering patients’ lives.
Sotatercept: A First-in-Class Treatment
Sotatercept, an activin A receptor IIA inhibitor, represents a groundbreaking advancement in the treatment of PAH. Thanks to the “first pilot, first trial” policy of Boao Lecheng Medical Tourism Pilot Zone, this first-in-class therapy will now be accessible to Chinese patients, offering new hope for those affected by this debilitating condition.-Fineline Info & Tech
Leave a Reply